PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic

Guido Eibl1, Dennis Bruemmer, Yuji Okada

  • 1Section of Gastrointestinal Surgery, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, 72-231 CHS, Los Angeles, CA 90095-6904, USA.

Insights

Cyclooxygenase-2 (COX-2) in pancreatic cancer cells produces prostaglandin E2 (PGE2). This PGE2 stimulates vascular endothelial growth factor (VEGF) secretion, promoting cancer cell growth and migration.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Cyclooxygenase (COX) inhibition shows anti-cancer effects in some tumors.
  • The role of COX-derived prostaglandins in pancreatic cancer (PaCa) remains unclear.

Purpose of the Study:

  • To investigate the expression and function of COX enzymes in pancreatic cancer cell lines.
  • To determine the effect of prostaglandin E2 (PGE2) on vascular endothelial growth factor (VEGF) synthesis and endothelial cell migration in PaCa.

Main Methods:

  • Detection of COX-1 and COX-2 expression in PaCa cell lines.
  • Measurement of PGE2 production stimulated by arachidonic acid (AA).
  • Assessment of VEGF synthesis and endothelial cell migration in response to AA, PGE2, and cAMP analogs.

Main Results:

  • COX-2 was detected in a subset of PaCa cell lines, correlating with PGE2 production.
  • PGE2, generated via COX-2 activity, increased VEGF synthesis through the EP2 receptor in a COX-2 dependent manner.
  • AA stimulation of COX-2 expressing PaCa cells enhanced endothelial cell migration, an effect blocked by COX-2 inhibition.

Conclusions:

  • A subset of human pancreatic cancer cell lines express functional COX-2.
  • COX-2-derived PGE2 plays a role in increasing VEGF secretion via an autocrine mechanism.
  • This suggests a potential therapeutic target for pancreatic cancer treatment.

Related Concept Videos

Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...